ATE422944T1 - Superoxiddismutas-mimetika zur behandlung von augenerkrankungen - Google Patents

Superoxiddismutas-mimetika zur behandlung von augenerkrankungen

Info

Publication number
ATE422944T1
ATE422944T1 AT02786915T AT02786915T ATE422944T1 AT E422944 T1 ATE422944 T1 AT E422944T1 AT 02786915 T AT02786915 T AT 02786915T AT 02786915 T AT02786915 T AT 02786915T AT E422944 T1 ATE422944 T1 AT E422944T1
Authority
AT
Austria
Prior art keywords
treatment
mimetics
eye diseases
dismutas
superoxide
Prior art date
Application number
AT02786915T
Other languages
English (en)
Inventor
Robert Collier
Mark Hellberg
Peter G Klimko
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ATE422944T1 publication Critical patent/ATE422944T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02786915T 2001-12-14 2002-12-06 Superoxiddismutas-mimetika zur behandlung von augenerkrankungen ATE422944T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34038901P 2001-12-14 2001-12-14

Publications (1)

Publication Number Publication Date
ATE422944T1 true ATE422944T1 (de) 2009-03-15

Family

ID=23333158

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02786915T ATE422944T1 (de) 2001-12-14 2002-12-06 Superoxiddismutas-mimetika zur behandlung von augenerkrankungen

Country Status (18)

Country Link
US (2) US7759333B2 (de)
EP (1) EP1463563B1 (de)
JP (1) JP2005513063A (de)
KR (1) KR100951606B1 (de)
CN (2) CN1620325A (de)
AT (1) ATE422944T1 (de)
BR (1) BR0214957A (de)
CA (1) CA2470721C (de)
CY (1) CY1108983T1 (de)
DE (1) DE60231246D1 (de)
DK (1) DK1463563T3 (de)
ES (1) ES2319399T3 (de)
MX (1) MXPA04005601A (de)
PL (1) PL210225B1 (de)
PT (1) PT1463563E (de)
SI (1) SI1463563T1 (de)
WO (1) WO2003051458A1 (de)
ZA (1) ZA200404435B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1620325A (zh) * 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
NZ593536A (en) 2008-12-19 2013-07-26 Genentech Inc Quinoline derivatives and methods of use
PT2433640T (pt) 2010-09-24 2020-04-03 Omnivision Gmbh Composição compreendendo sod, luteína e zeaxantina
KR101214364B1 (ko) * 2011-02-15 2012-12-21 한림대학교 산학협력단 수퍼옥사이드 디스뮤테이즈 융합 단백질을 함유하는 안과 질환 예방 또는 치료용 약제학적 조성물
CA2849456C (en) * 2011-09-26 2021-12-07 Galera Therapeutics, Llc Methods for treatment of diseases
KR102531246B1 (ko) * 2021-12-23 2023-05-11 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 건성 황반변성의 예방 또는 치료용 용도
CN119855604A (zh) * 2022-05-16 2025-04-18 杰诺福克斯有限公司 超氧化物歧化酶及其在预防或治疗糖尿病视网膜病变或葡萄膜炎中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
SE9402816D0 (sv) 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
JP2001521939A (ja) * 1997-11-03 2001-11-13 デューク・ユニバーシティー 置換されたポルフィリン類
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
US7445641B1 (en) 1999-05-27 2008-11-04 Pharmacia Corporation Biomaterials modified with superoxide dismutase mimics
CN1620325A (zh) * 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物

Also Published As

Publication number Publication date
JP2005513063A (ja) 2005-05-12
MXPA04005601A (es) 2004-12-06
BR0214957A (pt) 2004-12-14
ES2319399T3 (es) 2009-05-07
CA2470721C (en) 2011-07-12
PL210225B1 (pl) 2011-12-30
WO2003051458A1 (en) 2003-06-26
HK1069785A1 (en) 2005-06-03
US8003635B2 (en) 2011-08-23
US7759333B2 (en) 2010-07-20
EP1463563B1 (de) 2009-02-18
PL369607A1 (en) 2005-05-02
CN1620325A (zh) 2005-05-25
US20100204194A1 (en) 2010-08-12
US20050032768A1 (en) 2005-02-10
KR20040063943A (ko) 2004-07-14
CN101092432A (zh) 2007-12-26
CA2470721A1 (en) 2003-06-26
SI1463563T1 (sl) 2009-06-30
AU2002351267B2 (en) 2007-04-05
AU2002351267A1 (en) 2003-06-30
CY1108983T1 (el) 2014-07-02
KR100951606B1 (ko) 2010-04-09
DK1463563T3 (da) 2009-04-20
DE60231246D1 (de) 2009-04-02
ZA200404435B (en) 2006-05-31
EP1463563A1 (de) 2004-10-06
PT1463563E (pt) 2009-03-19

Similar Documents

Publication Publication Date Title
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
BR0317026A (pt) Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
DE60101265D1 (de) Behandlung von augenschmerzen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
GB0228410D0 (en) Novel Compounds
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
ATE258793T1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
ATE487482T1 (de) Superoxid-dismutase-mimika zur behandlungvon augenstörungen und erkrankungen
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
ATE253936T1 (de) Glutathion-reduktase zur behandlung und prophylaxe von aids
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
BRPI0417549A (pt) miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
DE60234031D1 (de) Mittel zur behandlung allergischer augenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1463563

Country of ref document: EP